People_

Professor Wendy Cooper

Clinical Professor
Sydney Medical School / Central Clinical School

Phone

02 95157458

wendy.cooper@sydney.edu.au

Professor Wendy Cooper is a Senior Staff Specialist in Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital; Anatomical Pathology Clinical Stream Lead for NSW Health Pathology; a Clinical Professor at the University of Sydney and a Conjoint Professor at the University of Western Sydney. Wendy graduated from Medicine at the University of Sydney with First Class Honours in 1998. She also received a Bachelor of Science (Med) with First Class Honours in 1996. She obtained her Fellowship from the Royal Australasian College of Pathologists in 2004 and in 2008 completed a PhD from the University of Sydney titled “Molecular markers of prognosis in early stage non-small cell lung cancer” for which she received the prestigious Peter Bancroft Prize.

Research interests

Lung cancer

Lymphoma

Teaching and supervision

Lung pathology

Haematopathology

Themes

Cancer

Keywords

Cancer, Genetics, Lung cancer, Molecular biology

Approaches

Pathology

Current research students

Project title	Research student
The Role of Co Mutations in clinical and pre clinical outcomes in KRAS mutant non small cell lung cancer.	Alex DAVIS

Publications

By Type

Expand all

Journals

Cooper, W., Yatabe, Y., Nicholson, A., Webster, F., Butnor, K., Calabrese, F., Chou, T., Hwang, D., Kern, I., Popat, S., et al (2024). Data set for the reporting of lung cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology. [More Information]
Barnes, H., Beckert, L., Milne, D., De Losa, R., Cooper, W., Bell, P., Balakrishnan, P., Troy, L., Corte, T., Keir, G., Limaye, S., et al (2024). Diagnosis and management of hypersensitivity pneumonitis in adults: A position statement from the Thoracic Society of Australia and New Zealand. Respirology. [More Information]
Klebe, S., Judge, M., Brcic, L., Dacic, S., Galateau-Salle, F., Nicholson, A., Roggli, V., Nowak, A., Cooper, W. (2024). Mesothelioma in the pleura, pericardium and peritoneum: Recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 84(4), 633-645. [More Information]
Kerr, K., Hofman, P., Cooper, W., Dacic, S., Bubendorf, L., Lopez-Rios, F., Khalil, F., Roy-Chowdhuri, S., Joubert, P., Hartmann, A., et al (2024). Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists. Histopathology, 84(3), 429-439. [More Information]
Li, J., Nindra, U., Vinod, S., French, B., Chua, W., Gupta, R., Cooper, W., Wang, B., Lee, C., Wu, X., et al (2024). The histopathological spectrum and molecular changes associated with KRAS G12C mutation in non-small cell lung carcinoma. Pathology. [More Information]
Fernando, C., Jayasekara, W., Inampudi, C., Kohonen-Corish, M., Cooper, W., Beilharz, T., Josephs, T., Garama, D., Gough, D. (2023). A STAT3 protein complex required for mitochondrial mRNA stability and cancer. Cell Reports, 42(9). [More Information]
Roden, A., Szolkowska, M., Cooper, W., Judge, M., den Bakker, M., Fang, W., Jain, D., Marx, A., Moreira, A., Rajan, A., et al (2023). Dataset for reporting of thymic epithelial tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 83(6), 967-980. [More Information]
Maleszewski, J., Basso, C., Burke, A., Castonguay, M., Leduc, C., Tavora, F., Sheppard, M., Suri, R., Judge, M., Cooper, W. (2023). Dataset for the reporting of neoplasms of the heart, pericardium, and great vessels: recommendations from the International Collaboration on Cancer Reporting (ICCR). Virchows Archiv, 482(2), 303-309. [More Information]
Chu, G., Linton, A., Kao, S., Klebe, S., Adelstein, S., Yeo, D., Rasko, J., Cooper, W. (2023). High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma. Histopathology. [More Information]
Dacic, S., Travis, W., Redman, M., Saqi, A., Cooper, W., Borczuk, A., Chung, J., Glass, C., Lopez, J., Roden, A., et al (2023). International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. Journal of Thoracic Oncology, 18(10), 1290-1302. [More Information]
McKenzie, C., Karim, R., Kench, J., Klebe, S., Kramer, N., Kumarasinghe, M., Maclean, F., Morey, A., Nguyen, M., O'Toole, S., Gupta, R., Salisbury, E., Scolyer, R., Cooper, W., Anderson, L., Chen, V., et al (2023). Looking beyond workforce parity: addressing gender inequity in pathology. Pathology, 55(6), 760-771. [More Information]
Nguyen, M., Colebatch, A., Van Beek, D., Tierney, G., Gupta, R., Cooper, W. (2023). NTRK fusions in solid tumours: what every pathologist needs to know. Pathology, 55(5), 596-609. [More Information]
Yu, S., Hsiao, Y., Cooper, W., Choi, Y., Avilés-Salas, A., Chou, T., Coudry, R., Raskin, G., Fox, S., Huang, C., et al (2023). The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer. Pathology, 55(1), 19-30. [More Information]
Clynick, B., Corte, T., Jo, H., Stewart, I., Glaspole, I., Grainge, C., Maher, T., Navaratnam, V., Hubbard, R., Hopkins, P., Cooper, W., et al (2022). Biomarker signatures for progressive idiopathic pulmonary fibrosis. European Respiratory Journal, 59(3), 1-12. [More Information]
Walsh, S., Mackintosh, J., Calandriello, L., Silva, M., Sverzellati, N., Larici, A., Humphries, S., Lynch, D., Jo, H., Glaspole, I., Cooper, W., et al (2022). Deep Learning-based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-Resolution Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 206(7), 883-891. [More Information]
Parker, A., Bowman, E., Zingone, A., Ryan, B., Cooper, W., Kohonen-Corish, M., Harris, C., Cox, T. (2022). Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma. Genome Medicine, 14(1). [More Information]
Potter, A., Colebatch, A., Rawson, R., Ferguson, P., Cooper, W., Gupta, R., O'Toole, S., Saw, R., Ch'ng, S., Menzies, A., Long, G., Scolyer, R. (2022). Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. Pathology, 54(5), 526-532. [More Information]
Woodford, R., Zhou, D., Lord, S., Marschner, I., Cooper, W., Lewis, C., John, T., Yang, J., Lee, C. (2022). PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. Future Oncology, 18(14), 1793-1799. [More Information]
Mino-Kenudson, M., Schalper, K., Cooper, W., Dacic, S., Hirsch, F., Jain, D., Lopez-Rios, F., Tsao, M., Yatabe, Y., Beasley, M., et al (2022). Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 17(12), 1335-1354. [More Information]
Fielder, T., Butler, J., Tierney, G., Holmes, M., Lam, K., Satgunaseelan, L., Colebatch, A., Mahar, A., Gupta, R., O'Toole, S., Cooper, W. (2022). ROS1 rearrangements in lung adenocarcinomas are defined by diffuse strong immunohistochemical expression of ROS1. Pathology, 54(4), 399-403. [More Information]
Heynemann, S., Prosser, N., Lee, J., Mahar, A., Anderson, L., Kao, S., Cooper, W. (2022). Squamous cell carcinoma differentiation at progression as a resistance mechanism in metastatic non-small cell lung carcinoma harbouring a targetable mutation. Pathology, 54(7), 935-938. [More Information]
McLean, A., Kao, S., Barnes, D., Wong, K., Scolyer, R., Cooper, W., Kohonen-Corish, M. (2022). The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment. Lung Cancer, 165, 124-132. [More Information]
Satgunaseelan, L., Strbenac, D., Willet, C., Chew, T., Sadsad, R., Wykes, J., Low, T., Cooper, W., Lee, C., Palme, C., Yang, J., Clark, J., Gupta, R. (2022). Whole genome duplication in oral squamous cell carcinoma in patients younger than 50 years: implications for prognosis and adverse clinicopathological factors. Genes Chromosomes and Cancer, 61(9), 561-571. [More Information]
Cooper, W., Mahar, A., Myers, J., Grainge, C., Corte, T., Williamson, J., Vallely, M., Lai, S., Mulyadi, E., Torzillo, P., Lau, E., Troy, L., et al (2021). Cryobiopsy for Identification of Usual Interstitial Pneumonia and Other Interstitial Lung Disease Features: Further Lessons from COLDICE, a Prospective Multi-Center Study. American Journal of Respiratory and Critical Care Medicine, 203(10), 1306-1313. [More Information]
Woodford, R., Lu, M., Beydoun, N., Cooper, W., Liu, Q., Lynch, J., Kasherman, L. (2021). Disseminated intravascular coagulation complicating diagnosis of ROS1-mutant non-small cell lung cancer: A case report and literature review. Thoracic Cancer, 12(17), 2400-2403. [More Information]
Davis, A., Cooper, W., Boyer, M., Lee, J., Pavlakis, N., Kao, S. (2021). Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations. Immunotherapy, 13(11), 941-952. [More Information]
Cooper, W., Mahar, A., Myers, J., Grainge, C., Corte, T., Williamson, J., Lau, E., Raghu, G., Troy, L. (2021). Letters to the Editor. Archives of Pathology & Laboratory Medicine, 145(11), 1326-1327. [More Information]
Hulme, K., Mahar, A., Cao, C., McCaughan, B., Cooper, W. (2021). Micronodular thymoma with lymphoid stroma: a clinicopathological study of five cases. Pathology, 53(7), 930-933. [More Information]
Aggarwal, C., Bubendorf, L., Cooper, W., Illei, P., Borralho Nunes, P., Ong, B., Tsao, M., Yatabe, Y., Kerr, K. (2021). Molecular testing in stage I–III non-small cell lung cancer: Approaches and challenges. Lung Cancer, 162, 42-53. [More Information]
Cooper, W., Lantuejoul, S., Mino-Kenudson, M. (2021). Predicting Response to Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Blockade in NSCLC—Is Multiplex Immunohistochemistry or Immunofluorescence the Answer? Journal of Thoracic Oncology, 16(8), 1247-1249. [More Information]
Meyer, N., Cooper, W., Kirwan, P., Garsia, R., Dunkley, S., Gracey, D. (2021). Primary membranous glomerulonephritis with negative serum PLA2R in haemophilia A successfully managed with rituximab - case report and review of the literature. BMC Nephrology, 22(1), 268. [More Information]
Paver, E., Cooper, W., Colebatch, A., Ferguson, P., Hill, S., Lum, T., Shin, J., O'Toole, S., Anderson, L., Scolyer, R., Gupta, R. (2021). Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology, 53(2), 141-156. [More Information]
Holmes, M., Mahar, A., Lum, T., Kao, S., Cooper, W. (2021). Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: Correlation with clinicopathological features and tumour mutation status. Journal of Clinical Pathology, 74(2), 123-128. [More Information]
Liu, J., Itchins, M., Nagrial, A., Cooper, W., De Silva, M., Barnet, M., Varikatt, W., Sivasubramaniam, V., Davis, A., Gill, A., Blinman, P., Lee, K., Hui, R., Pavlakis, N., Clarke, S., Boyer, M., Kao, S., et al (2021). Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. Lung Cancer, 155, 28-33. [More Information]
Pang, J., Castles, B., Byrne, D., Button, P., Hendry, S., Lakhani, S., Sivasubramaniam, V., Cooper, W., Armes, J., Millar, E., Chan, C., Beith, J., et al (2021). SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3. The American Journal of Surgical Pathology, 45(8), 1108-1117. [More Information]
Mino-Kenudson, M., Le Stang, N., Daigneault, J., Nicholson, A., Cooper, W., Roden, A., Moreira, A., Thunnissen, E., Papotti, M., Pelosi, G., et al (2021). The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. Journal of Thoracic Oncology, 16(4), 686-696. [More Information]
Paver, E., O'Toole, S., Cheng, X., Mahar, A., Cooper, W. (2021). Updates in the molecular pathology of non-small cell lung cancer. Seminars in Diagnostic Pathology, 38(5), 54-61. [More Information]
Moreira, A., Ocampo, P., Xia, Y., Zhong, H., Russell, P., Minami, Y., Cooper, W., Yoshida, A., Bubendorf, L., Papotti, M., et al (2020). A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 15(10), 1599-1610. [More Information]
Hendry, S., Byrne, N., Christie, M., Steinfort, D., Irving, L., Wagner, C., Ellwood, T., Cooper, W., Fox, S. (2020). Adequate tumour cellularity is essential for accurate PD-L1 immunohistochemistry assessment on cytology cell block specimens. Cytopathology, 31(2), 90-95. [More Information]
Itchins, M., Lau, B., Hudson, A., Westman, H., Xia, C., Hayes, S., Howell, V., Rodriguez, M., Cooper, W., Wei, G., Buckland, M., Li, B., Gill, A., Clarke, S., Pavlakis, N., et al (2020). ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. The Oncologist, 25(8), 641-649. [More Information]
Teoh, A., Jo, H., Chambers, D., Symons, K., Walters, E., Goh, N., Glaspole, I., Cooper, W., Reynolds, P., Moodley, Y., Corte, T. (2020). Blood monocyte counts as a potential prognostic marker for IPF: Analysis from the Australian IPF registry. European Respiratory Journal, 55(4), 1901855. [More Information]
Clynick, B., Jo, H., Corte, T., Glaspole, I., Grainge, C., Hopkins, P., Reynolds, P., Chapman, S., Haydn Walters, E., Zappala, C., Cooper, W., Mahar, A., et al (2020). Circulating RNA differences between patients with stable and progressive idiopathic pulmonary fibrosis. European Respiratory Journal, 56(3), 1902058. [More Information]
Troy, L., Grainge, C., Corte, T., Williamson, J., Vallely, M., Cooper, W., Mahar, A., Myers, J., Lai, S., Mulyadi, E., Torzillo, P., Jo, H., Harris, B., Lau, E., et al (2020). Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. The Lancet Respiratory Medicine, 8(2), 171-181. [More Information]
Smith, M., Hariri, L., Mino-Kenudson, M., Dacic, S., Attanoos, R., Borczuk, A., Colby, T., Cooper, W., Jones, K., Leslie, K., et al (2020). Histopathologic assessment of suspected idiopathic pulmonary fibrosis: Where we are and where we need to go. Archives of Pathology & Laboratory Medicine, 144(12), 1477-1489. [More Information]
Travis, W., Dacic, S., Wistuba, I., Sholl, L., Adusumilli, P., Bubendorf, L., Bunn, P., Cascone, T., Chaft, J., Chen, G., Cooper, W., et al (2020). IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 15(5), 709-740. [More Information]
John, T., Cooper, W., Wright, G., Siva, S., Solomon, B., Marshall, H., Fong, K. (2020). Lung Cancer in Australia. Journal of Thoracic Oncology, 15(12), 1809-1814. [More Information]
Lau, E., Grainge, C., Williamson, J., Corte, T., Cooper, W., Phillips, M., Torzillo, P., Vallely, M., Raghu, G., Troy, L. (2020). Methodologies of COLDICE and Cryo-PID studies: details make the difference. Annals of Translational Medicine, 8(12), 781. [More Information]
Ahmadzada, T., Cooper, W., Holmes, M., Mahar, A., Westman, H., Gill, A., Nordman, I., Yip, P., Pal, A., Zielinski, R., Pavlakis, N., Nagrial, A., Daneshvar, D., Karikios, D., Grau, G., Hosseini Beheshti, E., Clarke, S., Kao, S., et al (2020). Retrospective evaluation of the use of pembrolizumab in malignant mesothelioma in a real-world Australian population. JTO Clinical and Research Reports, 1(4), 1-15. [More Information]
Li, Z., Abadir, E., Lee, K., Clarke, C., Bryant, C., Cooper, W., Pietersz, G., Favaloro, J., Silveira, P., Hart, D., Ju, X., Clark, G. (2020). Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody. Clinical & Translational Immunology, 9(7), 1-12. [More Information]
Sholl, L., Hirsch, F., Hwang, D., Botling, J., Lopez-Rios, F., Bubendorf, L., Mino-Kenudson, M., Roden, A., Beasley, M., Borczuk, A., Cooper, W., et al (2020). The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 15(9), 1409-1424. [More Information]
Pavlakis, N., Cooper, C., John, T., Kao, S., Klebe, S., Lee, C., Leong, T., Millward, M., O'Byrne, K., Russell, P., Cooper, W., et al (2019). Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. Pathology, 51(7), 673-680. [More Information]
Luk, P., Selinger, C., Cooper, W., Mahar, A., Palme, C., O'Toole, S., Clark, J., Gupta, R. (2019). Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms. Head and Neck Pathology, 13(3), 397-414. [More Information]
Troy, L., Grainge, C., Corte, T., Williamson, J., Vallely, M., Cooper, W., Mahar, A., Lai, S., Mulyadi, E., Torzillo, P., Lau, E., et al (2019). Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study. BMJ Open Respiratory Research, 6(1), 1-8. [More Information]
Burgess, A., Goon, K., Brannan, J., Attia, J., Palazzi, K., Oldmeadow, C., Corte, T., Glaspole, I., Goh, N., Keir, G., Cooper, W., et al (2019). Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing. Respirology, 24(10), 988-995. [More Information]
Vargas, A., Selinger, C., Satgunaseelan, L., Cooper, W., Gupta, R., Stalley, P., Brown, W., Soper, J., Schatz, J., Boyle, R., Tattersall, M., Bhadri, V., Scolyer, R., Karim, R., McCarthy, S., O'Toole, S., et al (2019). FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. Asia-Pacific Journal of Clinical Oncology, 15(1), 38-47. [More Information]
Jo, H., Corte, T., Glaspole, I., Grainge, C., Hopkins, P., Moodley, Y., Chapman, S., Walters, E., Zappala, C., Allan, H., Cooper, W., Goh, N., et al (2019). Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry. BMC Pulmonary Medicine, 19(1), 1-7. [More Information]
Ahmadzada, T., Lee, K., Clarke, C., Cooper, W., Linton, A., McCaughan, B., Asher, R., Clarke, S., Reid, G., Kao, S. (2019). High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. Lung Cancer, 130, 35-41. [More Information]
Jo, H., Glaspole, I., Goh, N., Hopkins, P., Moodley, Y., Reynolds, P., Chapman, S., Walters, E., Zappala, C., Allan, H., Grainge, C., Cooper, W., Corte, T., et al (2019). Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Respirology, 24(4), 361-368. [More Information]
Toon, C., Cooper, W., Selinger, C., Berney, C., Tomlinson, J. (2019). Malignant gastrointestinal neuroectodermal tumour (GNET): neural mesenchymal tumours of the gastrointestinal tract with striking histology and EWSR1 gene rearrangement. Pathology, 51(3), 324-327. [More Information]
Woodford, R., Loh, Y., Lee, J., Cooper, W., Marschner, I., Lewis, C., Millward, M., Lord, S., Gralla, R., Yang, J., Lee, C., et al (2019). Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. Future Oncology, 15(20), 2371-2383. [More Information]
Colebatch, A., Dobrovic, A., Cooper, W. (2019). TERT gene: Its function and dysregulation in cancer. Journal of Clinical Pathology, 72(4), 281-284. [More Information]
Ahmadzada, T., Kao, S., Reid, G., Boyer, M., Mahar, A., Cooper, W. (2018). An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 7(6), E153. [More Information]
Luk, P., Selinger, C., Mahar, A., Cooper, W. (2018). Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization. Archives of Pathology & Laboratory Medicine, 142(8), 922-928. [More Information]
Cooper, W., Barnet, M., Kao, S., Scolyer, R. (2018). Biomarkers that predict response to immunotherapy-no magic bullet. Cancer Forum, 42(1), 1-10. [More Information]
Li, Z., Ju, X., Lee, K., Clarke, C., Hsu, J., Abadir, E., Bryant, C., Pears, S., Sunderland, N., Heffernan, S., Lo, T., Fromm, P., Silveira, P., Cooper, W., Brown, C., Clark, G., Hart, D., et al (2018). CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. Haematologica, 103(4), 655-665. [More Information]
Lee, C., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., Herbst, R., Gralla, R., Mok, T., Yang, J. (2018). Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncology, 4(2), 210-216. [More Information]
Hendry, S., Byrne, D., Wright, G., Young, R., Sturrock, S., Cooper, W., Fox, S. (2018). Comparison of four PD-L1 immunohistochemical assays in lung cancer. Journal of Thoracic Oncology, 13(3), 367-376. [More Information]
Jo, H., Glaspole, I., Moodley, Y., Chapman, S., Ellis, S., Goh, N., Hopkins, P., Keir, G., Mahar, A., Cooper, W., Corte, T., et al (2018). Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulmonary Medicine, 18(1), 1-8. [More Information]
Gupta, R., Cooper, W., Selinger, C., Mahar, A., Anderson, L., Buckland, M., O'Toole, S. (2018). Fluorescent In Situ Hybridization in Surgical Pathology Practice. Advances in Anatomic Pathology, 25(4), 223-237. [More Information]
Thunnissen, E., Allen, T., Adam, J., Aisner, D., Beasley, M., Borczuk, A., Cagle, P., Capelozzi, V., Cooper, W., Hariri, L., et al (2018). Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology & Laboratory Medicine, 142(3), 408-419. [More Information]
Barnet, M., Cooper, W., Boyer, M., Kao, S. (2018). Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. Journal of Clinical Medicine, 7(6), 151. [More Information]
Itchins, M., Hayes, S., Gill, A., Cooper, W., O'Connell, R., Howell, V., Clarke, S., Pavlakis, N. (2018). Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. Asia-Pacific Journal of Clinical Oncology, 14(5), e275-e282. [More Information]
Solinas, A., Mahar, A., Cooper, W., Thompson, J., Spillane, A., Scolyer, R. (2018). Pigmented Paget's disease of the nipple mistaken for melanoma in situ: a diagnostic pitfall for the unwary. Pathology, 50(3), 364-367. [More Information]
Hendry, S., Cooper, W., Fox, S. (2018). Response to Editorial: The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back? Journal of Thoracic Oncology, 13(9), e185-e186. [More Information]
Bui, K., Cooper, W., Kao, S., Boyer, M. (2018). Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. Journal of Clinical Medicine, 7(8), 1-18. [More Information]
Barnet, M., Blinman, P., Cooper, W., Boyer, M., Kao, S., Goodnow, C. (2018). Understanding Immune Tolerance of Cancer: Re-Purposing Insights from Fetal Allografts and Microbes. BioEssays, 40(8), 1-6. [More Information]
Jo, H., Glaspole, I., Grainge, C., Goh, N., Hopkins, P., Moodley, Y., Reynolds, P., Chapman, S., Walters, E., Cooper, W., Corte, T., et al (2017). Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal, 49(2), 1-11. [More Information]
Glaspole, I., Watson, A., Allan, H., Chapman, S., Cooper, W., Corte, T., Ellis, S., Grainge, C., Goh, N., Hopkins, P., Mahar, A., et al (2017). Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. European Respiratory Journal, 50(2), pii: 1700168. [More Information]
Barnet, M., O'Toole, S., Horvath, L., Selinger, C., Yu, B., Ng, C., Boyer, M., Cooper, W., Kao, S. (2017). EGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 12(3), 585-590. [More Information]
Sebaratnam, D., Agar, N., Cooper, W., Jackett, L. (2017). Eruptive Multifocal Cutaneous Mucinous Cysts. American Journal Of Dermatopathology, 2(6), 454-456. [More Information]
Glaspole, I., Chapman, S., Cooper, W., Ellis, S., Goh, N., Hopkins, P., Macansh, S., Mahar, A., Moodley, Y., Paul, E., Corte, T., et al (2017). Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry. Respirology, 22(5), 950-956. [More Information]
Cooper, W., Russell, P., Cherian, M., Duhig, E., Godbolt, D., Jessup, P., Khoo, C., Leslie, C., Mahar, A., Moffat, D., et al (2017). Intra- and interobserver reproducibility assessment of PD-L1 biomarker in non-small cell lung cancer. Clinical Cancer Research, 23(16), 4569-4577. [More Information]
Shakya, R., Tarulli, G., Sheng, L., Lokman, N., Ricciardelli, C., Pishas, K., Selinger, C., Kohonen-Corish, M., Cooper, W., Turner, A., et al (2017). Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer. Oncogene, 36(31), 4469-4480. [More Information]
van Zandwijk, N., Pavlakis, N., Kao, S., Linton, A., Boyer, M., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M., Bailey, D., Cooper, W., Kritharides, L., Reid, G., et al (2017). Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. The Lancet Oncology, 18(10), 1386-1396. [More Information]
Selinger, C., Li, B., Pavlakis, N., Links, M., Gill, A., Lee, A., Clarke, S., Tran, T., Lum, T., Yip, P., Horvath, L., Yu, B., O'Toole, S., Cooper, W., et al (2017). Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. Histopathology, 70(3), 402-411. [More Information]
Satgunaseelan, L., Larsen, S., Carmalt, H., Cooper, W. (2017). Spindle cell variant of diffuse large B cell lymphoma occurring in the breast. Pathology, 49(7), 784-786. [More Information]
Herath, S., Cooper, W. (2017). The novel 19G endobronchial USS (EBUS) needle samples processed as tissue “core biopsies” facilitate PD-L1 and other biomarker testing in lung cancer specimens: Case report and the view point from the respiratory physician and the pathologist. Respirology Case Reports, 5(6), 1-3. [More Information]
Szczepny, A., Rogers, S., Jayasekara, W., Park, K., McCloy, R., Cochrane, C., Ganju, V., Cooper, W., Sage, J., Peacock, C., et al (2017). The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer. Oncogene, 36(39), 5544-5550. [More Information]
Thunnissen, E., Borczuk, A., Flieder, D., Witte, B., Beasley, M., Chung, J., Dacic, S., Lantuejoul, S., Russell, P., Cooper, W., et al (2017). The use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and its Differential Diagnosis. An international reproducibility study in a demanding set of cases. Journal of Thoracic Oncology, 12(2), 334-346. [More Information]
Itchins, M., Chia, P., Hayes, S., Howell, V., Gill, A., Cooper, W., John, T., Mitchell, P., Millward, M., Clarke, S., Pavlakis, N., et al (2017). Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context. Asia-Pacific Journal of Clinical Oncology, 13, 3-13. [More Information]
Kao, S., Cheng, Y., Williams, M., Kirschner, M., Madore, J., Lum, T., Sarun, K., Linton, A., McCaughan, B., Klebe, S., van Zandwijk, N., Scolyer, R., Boyer, M., Cooper, W., Reid, G. (2017). Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 12(9), 1421-1433. [More Information]
Kao, S., Kirschner, M., Cooper, W., Tran, T., Burgers, S., Wright, C., Korse, T., van den Broek, D., Edelman, J., Vallely, M., McCaughan, B., Pavlakis, N., Clarke, S., van Zandwijk, N., Reid, G., et al (2016). A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. British Journal of Cancer, 114(5), 524-531. [More Information]
Tran, T., Selinger, C., Kohonen-Corish, M., McCaughan, B., Kennedy, C., O'Toole, S., Cooper, W. (2016). Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases. Clinical Lung Cancer, 17(1), 30-38. [More Information]
Vargas, A., Selinger, C., Satgunaseelan, L., Cooper, W., Gupta, R., Stalley, P., Brown, W., Soper, J., Schatz, J., Boyle, R., Tattersall, M., Bhadri, V., Scolyer, R., Karim, R., McCarthy, S., O'Toole, S., et al (2016). Atypical Ewing sarcoma breakpoint region 1 fluorescence in-situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases. Histopathology, 69(6), 1000-1011. [More Information]
Kakavand, H., Walker, E., Lum, T., Wilmott, J., Selinger, C., Smith, E., Saw, R., Yu, B., Cooper, W., Long, G., O'Toole, S., Scolyer, R. (2016). BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Histopathology, 69(4), 680-686. [More Information]
Jo, H., Glaspole, I., Levin, K., McCormack, S., Mahar, A., Cooper, W., Cameron, R., Ellis, S., Cottee, A., Troy, L., Torzillo, P., Corte, T., et al (2016). Clinical impact of the interstitial lung disease multidisciplinary service. Respirology, 21(8), 1438-1444. [More Information]
Anderson, S., Sasson, S., Lee, F., Cooper, W., Larsen, S., Garsia, R. (2016). Episodic fevers and vasodilatory shock mimicking urosepsis in a patient with HIV-associated multicentric Castleman's Disease: a case report. BMC Infectious Diseases, 16(1), 53. [More Information]
Lyle, M., Haydu, L., Menzies, A., Thompson, J., Saw, R., Spillane, A., Kefford, R., Mann, G., Cooper, W., Yu, B., Scolyer, R., O'Toole, S., Long, G. (2016). The molecular profile of metastatic melanoma in Australia. Pathology, 48(2), 188-193. [More Information]
Bremnes, R., Busund, L., Kilvaer, T., Andersen, S., Richardsen, E., Paulsen, E., Hald, S., Khanehkenari, M., Cooper, W., Kao, S., et al (2016). The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. Journal of Thoracic Oncology, 11(6), 789-800. [More Information]
Kao, S., Fulham, M., Wong, K., Cooper, W., Brahmbhatt, H., MacDiarmid, J., Pattison, S., Sagong, J., Huynh, Y., Leslie, F., Pavlakis, N., Clarke, S., Boyer, M., Reid, G., van Zandwijk, N. (2015). A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. American Journal of Respiratory and Critical Care Medicine, 191(12), 1467-1469. [More Information]
Luk, P., Yu, B., Ng, C., Mercorella, B., Selinger, C., Lum, T., Kao, S., O'Toole, S., Cooper, W. (2015). BRAF mutations in non-small cell lung cancer. Translational Lung Cancer Research, 4(2), 142-148. [More Information]
Selinger, C., Cooper, W., Lum, T., McNeil, C., Morey, A., Waring, P., Amanuel, B., Millward, M., Peverall, J., Van Vliet, C., Pavlakis, N., Gill, A., et al (2015). Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing. Histopathology, 67(5), 654-663. [More Information]
Li, B., Lee, A., O'Toole, S., Cooper, W., Yu, B., Chaft, J., Arcila, M., Kris, M., Pavlakis, N. (2015). HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. Lung Cancer, 90(3), 617-619. [More Information]
Williams, M., Kirschner, M., Cheng, Y., Hanh, J., Weiss, J., Amaro-Mugridge, N., Wright, C., Linton, A., Kao, S., Edelman, J., Vallely, M., Cooper, W., van Zandwijk, N., Reid, G., et al (2015). miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget, 6(27), 23480-23495. [More Information]
Cooper, W., Tran, T., Vilain, R., Madore, J., Selinger, C., Kohonen-Corish, M., Yip, P., Yu, B., O'Toole, S., McCaughan, B., Horvath, L., Kao, S., Boyer, M., Scolyer, R., et al (2015). PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer, 89(2), 181-188. [More Information]
Cooper, W. (2015). Preface-molecular genetics of lung cancer. Translational Lung Cancer Research, 4(2), 109-109. [More Information]
Wang, S., Yu, B., Ng, C., Mercorella, B., Selinger, C., O'Toole, S., Cooper, W. (2015). The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer. Translational Lung Cancer Research, 4(2), 119-125. [More Information]
Tran, T., Selinger, C., Yu, B., Ng, C., Kohonen-Corish, M., McCaughan, B., Kennedy, C., O'Toole, S., Cooper, W. (2014). Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer. Journal of Clinical Pathology, 67(11), 985-991. [More Information]
Moodley, Y., Goh, N., Glaspole, I., Macansh, S., Walters, E., Chapman, S., Hopkins, P., Reynolds, P., Zappala, C., Cooper, W., Mahar, A., Corte, T., et al (2014). Australian Idiopathic Pulmonary Fibrosis Registry: Vital lessons from a national prospective collaborative project. Respirology, 19(7), 1088-1091. [More Information]
Carlino, M., Haydu, L., Kakavand, H., Menzies, A., Hamilton, A., Yu, B., Ng, C., Cooper, W., Thompson, J., Kefford, R., O'Toole, S., Scolyer, R., Long, G. (2014). Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 111(2), 292-299. [More Information]
Houang, M., Sioson, L., Clarkson, A., Watson, N., Mahtab, F., Toon, C., Raut, A., O'Toole, S., Cooper, W., Pavlakis, N., Gill, A., et al (2014). EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Pathology, 46(6), 501-508. [More Information]
O'Toole, S., Yu, B., Cooper, W. (2014). Molecular Diagnosis in Cytology and Its Place in the New Classification: A Practical Guide. The Journal of OncoPathology, 2(1), 63-73. [More Information]
Cooper, W., Fox, S., O'Toole, S., Morey, A., Frances, G., Pavlakis, N., O'Brien, K., Dettrick, A., Leong, T., Rathi, V., et al (2014). National Working Group Meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology, 10(S 2), 11-17. [More Information]
Houang, M., Toon, C., Clarkson, A., Sioson, L., Watson, N., Farzin, M., Selinger, C., Chou, A., Morey, A., Cooper, W., O'Toole, S., Gill, A. (2014). Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer. Pathology, 46(5), 383-388. [More Information]
Cooper, W., Solomon, B. (2014). Response to Mahe. Modern Pathology, 27(10), 1424-1425. [More Information]
Cooper, W., Yu, B., Yip, P., Ng, C., Lum, T., Farzin, M., Trent, R., Mercorella, B., Clarkson, A., Kohonen-Corish, M., Horvath, L., Kench, J., McCaughan, B., Gill, A., O'Toole, S. (2013). EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. Journal of Clinical Pathology, 66(9), 744-748. [More Information]
Tran, T., Selinger, C., Kohonen-Corish, M., McCaughan, B., Kennedy, C., O'Toole, S., Cooper, W. (2013). Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer, 81(3), 462-467. [More Information]
Cooper, W., Lam, D., O'Toole, S., Minna, J. (2013). Molecular biology of lung cancer. Journal of Thoracic Disease, 5(S5), S479-S490. [More Information]
Poursoltana, P., Currey, N., Pangon, L., van Kralingen, C., Selinger, C., Mahar, A., Cooper, W., Kennedy, C., McCaughan, B., Trent, R., et al (2012). Loss of heterozygosity of the Mutated in Colorectal Cancer gene is not associated with promoter methylation in non-small cell lung cancer. Lung Cancer, 77(2), 272-276. [More Information]
Wang, Y., Sebaratnam, D., Wong, J., Cooper, W., Wyburn, K., Eris, J. (2012). Urethral Stricture Caused by Schistosomiasis in a Renal Transplant Recipient. Nephrology, 17(2), 197-198. [More Information]
Lau, E., Cooper, W., Bye, P., Yan, K. (2011). Difficult asthma and Churg-Strauss-like syndrome: A cautionary tale. Respirology, 16(1), 180-181. [More Information]
Cooper, W., O'Toole, S., Boyer, M., Horvath, L., Mahar, A. (2011). What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 43(2), 103-115. [More Information]
Cooper, W., Shingde, M., Lee, V., Allan, R., Wills, E., Harper, C. (2004). "Rhabdoid Meningioma" Lacking Malignant Features. Report Of Two Cases. Clinical Neuropathology, 23(1), 16-20.

show 120 more

By Year

Expand all

2024

Cooper, W., Yatabe, Y., Nicholson, A., Webster, F., Butnor, K., Calabrese, F., Chou, T., Hwang, D., Kern, I., Popat, S., et al (2024). Data set for the reporting of lung cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology. [More Information]
Barnes, H., Beckert, L., Milne, D., De Losa, R., Cooper, W., Bell, P., Balakrishnan, P., Troy, L., Corte, T., Keir, G., Limaye, S., et al (2024). Diagnosis and management of hypersensitivity pneumonitis in adults: A position statement from the Thoracic Society of Australia and New Zealand. Respirology. [More Information]
Klebe, S., Judge, M., Brcic, L., Dacic, S., Galateau-Salle, F., Nicholson, A., Roggli, V., Nowak, A., Cooper, W. (2024). Mesothelioma in the pleura, pericardium and peritoneum: Recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 84(4), 633-645. [More Information]
Kerr, K., Hofman, P., Cooper, W., Dacic, S., Bubendorf, L., Lopez-Rios, F., Khalil, F., Roy-Chowdhuri, S., Joubert, P., Hartmann, A., et al (2024). Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists. Histopathology, 84(3), 429-439. [More Information]
Li, J., Nindra, U., Vinod, S., French, B., Chua, W., Gupta, R., Cooper, W., Wang, B., Lee, C., Wu, X., et al (2024). The histopathological spectrum and molecular changes associated with KRAS G12C mutation in non-small cell lung carcinoma. Pathology. [More Information]

show 2 more

2023

Fernando, C., Jayasekara, W., Inampudi, C., Kohonen-Corish, M., Cooper, W., Beilharz, T., Josephs, T., Garama, D., Gough, D. (2023). A STAT3 protein complex required for mitochondrial mRNA stability and cancer. Cell Reports, 42(9). [More Information]
Roden, A., Szolkowska, M., Cooper, W., Judge, M., den Bakker, M., Fang, W., Jain, D., Marx, A., Moreira, A., Rajan, A., et al (2023). Dataset for reporting of thymic epithelial tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 83(6), 967-980. [More Information]
Maleszewski, J., Basso, C., Burke, A., Castonguay, M., Leduc, C., Tavora, F., Sheppard, M., Suri, R., Judge, M., Cooper, W. (2023). Dataset for the reporting of neoplasms of the heart, pericardium, and great vessels: recommendations from the International Collaboration on Cancer Reporting (ICCR). Virchows Archiv, 482(2), 303-309. [More Information]
Chu, G., Linton, A., Kao, S., Klebe, S., Adelstein, S., Yeo, D., Rasko, J., Cooper, W. (2023). High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma. Histopathology. [More Information]
Dacic, S., Travis, W., Redman, M., Saqi, A., Cooper, W., Borczuk, A., Chung, J., Glass, C., Lopez, J., Roden, A., et al (2023). International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. Journal of Thoracic Oncology, 18(10), 1290-1302. [More Information]
McKenzie, C., Karim, R., Kench, J., Klebe, S., Kramer, N., Kumarasinghe, M., Maclean, F., Morey, A., Nguyen, M., O'Toole, S., Gupta, R., Salisbury, E., Scolyer, R., Cooper, W., Anderson, L., Chen, V., et al (2023). Looking beyond workforce parity: addressing gender inequity in pathology. Pathology, 55(6), 760-771. [More Information]
Nguyen, M., Colebatch, A., Van Beek, D., Tierney, G., Gupta, R., Cooper, W. (2023). NTRK fusions in solid tumours: what every pathologist needs to know. Pathology, 55(5), 596-609. [More Information]
Yu, S., Hsiao, Y., Cooper, W., Choi, Y., Avilés-Salas, A., Chou, T., Coudry, R., Raskin, G., Fox, S., Huang, C., et al (2023). The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer. Pathology, 55(1), 19-30. [More Information]

show 5 more

2022

Clynick, B., Corte, T., Jo, H., Stewart, I., Glaspole, I., Grainge, C., Maher, T., Navaratnam, V., Hubbard, R., Hopkins, P., Cooper, W., et al (2022). Biomarker signatures for progressive idiopathic pulmonary fibrosis. European Respiratory Journal, 59(3), 1-12. [More Information]
Walsh, S., Mackintosh, J., Calandriello, L., Silva, M., Sverzellati, N., Larici, A., Humphries, S., Lynch, D., Jo, H., Glaspole, I., Cooper, W., et al (2022). Deep Learning-based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-Resolution Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 206(7), 883-891. [More Information]
Parker, A., Bowman, E., Zingone, A., Ryan, B., Cooper, W., Kohonen-Corish, M., Harris, C., Cox, T. (2022). Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma. Genome Medicine, 14(1). [More Information]
Potter, A., Colebatch, A., Rawson, R., Ferguson, P., Cooper, W., Gupta, R., O'Toole, S., Saw, R., Ch'ng, S., Menzies, A., Long, G., Scolyer, R. (2022). Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. Pathology, 54(5), 526-532. [More Information]
Woodford, R., Zhou, D., Lord, S., Marschner, I., Cooper, W., Lewis, C., John, T., Yang, J., Lee, C. (2022). PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. Future Oncology, 18(14), 1793-1799. [More Information]
Mino-Kenudson, M., Schalper, K., Cooper, W., Dacic, S., Hirsch, F., Jain, D., Lopez-Rios, F., Tsao, M., Yatabe, Y., Beasley, M., et al (2022). Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 17(12), 1335-1354. [More Information]
Fielder, T., Butler, J., Tierney, G., Holmes, M., Lam, K., Satgunaseelan, L., Colebatch, A., Mahar, A., Gupta, R., O'Toole, S., Cooper, W. (2022). ROS1 rearrangements in lung adenocarcinomas are defined by diffuse strong immunohistochemical expression of ROS1. Pathology, 54(4), 399-403. [More Information]
Heynemann, S., Prosser, N., Lee, J., Mahar, A., Anderson, L., Kao, S., Cooper, W. (2022). Squamous cell carcinoma differentiation at progression as a resistance mechanism in metastatic non-small cell lung carcinoma harbouring a targetable mutation. Pathology, 54(7), 935-938. [More Information]
McLean, A., Kao, S., Barnes, D., Wong, K., Scolyer, R., Cooper, W., Kohonen-Corish, M. (2022). The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment. Lung Cancer, 165, 124-132. [More Information]
Satgunaseelan, L., Strbenac, D., Willet, C., Chew, T., Sadsad, R., Wykes, J., Low, T., Cooper, W., Lee, C., Palme, C., Yang, J., Clark, J., Gupta, R. (2022). Whole genome duplication in oral squamous cell carcinoma in patients younger than 50 years: implications for prognosis and adverse clinicopathological factors. Genes Chromosomes and Cancer, 61(9), 561-571. [More Information]

show 7 more

2021

Cooper, W., Mahar, A., Myers, J., Grainge, C., Corte, T., Williamson, J., Vallely, M., Lai, S., Mulyadi, E., Torzillo, P., Lau, E., Troy, L., et al (2021). Cryobiopsy for Identification of Usual Interstitial Pneumonia and Other Interstitial Lung Disease Features: Further Lessons from COLDICE, a Prospective Multi-Center Study. American Journal of Respiratory and Critical Care Medicine, 203(10), 1306-1313. [More Information]
Woodford, R., Lu, M., Beydoun, N., Cooper, W., Liu, Q., Lynch, J., Kasherman, L. (2021). Disseminated intravascular coagulation complicating diagnosis of ROS1-mutant non-small cell lung cancer: A case report and literature review. Thoracic Cancer, 12(17), 2400-2403. [More Information]
Davis, A., Cooper, W., Boyer, M., Lee, J., Pavlakis, N., Kao, S. (2021). Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations. Immunotherapy, 13(11), 941-952. [More Information]
Cooper, W., Mahar, A., Myers, J., Grainge, C., Corte, T., Williamson, J., Lau, E., Raghu, G., Troy, L. (2021). Letters to the Editor. Archives of Pathology & Laboratory Medicine, 145(11), 1326-1327. [More Information]
Hulme, K., Mahar, A., Cao, C., McCaughan, B., Cooper, W. (2021). Micronodular thymoma with lymphoid stroma: a clinicopathological study of five cases. Pathology, 53(7), 930-933. [More Information]
Aggarwal, C., Bubendorf, L., Cooper, W., Illei, P., Borralho Nunes, P., Ong, B., Tsao, M., Yatabe, Y., Kerr, K. (2021). Molecular testing in stage I–III non-small cell lung cancer: Approaches and challenges. Lung Cancer, 162, 42-53. [More Information]
Cooper, W., Lantuejoul, S., Mino-Kenudson, M. (2021). Predicting Response to Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Blockade in NSCLC—Is Multiplex Immunohistochemistry or Immunofluorescence the Answer? Journal of Thoracic Oncology, 16(8), 1247-1249. [More Information]
Meyer, N., Cooper, W., Kirwan, P., Garsia, R., Dunkley, S., Gracey, D. (2021). Primary membranous glomerulonephritis with negative serum PLA2R in haemophilia A successfully managed with rituximab - case report and review of the literature. BMC Nephrology, 22(1), 268. [More Information]
Paver, E., Cooper, W., Colebatch, A., Ferguson, P., Hill, S., Lum, T., Shin, J., O'Toole, S., Anderson, L., Scolyer, R., Gupta, R. (2021). Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology, 53(2), 141-156. [More Information]
Holmes, M., Mahar, A., Lum, T., Kao, S., Cooper, W. (2021). Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: Correlation with clinicopathological features and tumour mutation status. Journal of Clinical Pathology, 74(2), 123-128. [More Information]
Liu, J., Itchins, M., Nagrial, A., Cooper, W., De Silva, M., Barnet, M., Varikatt, W., Sivasubramaniam, V., Davis, A., Gill, A., Blinman, P., Lee, K., Hui, R., Pavlakis, N., Clarke, S., Boyer, M., Kao, S., et al (2021). Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. Lung Cancer, 155, 28-33. [More Information]
Pang, J., Castles, B., Byrne, D., Button, P., Hendry, S., Lakhani, S., Sivasubramaniam, V., Cooper, W., Armes, J., Millar, E., Chan, C., Beith, J., et al (2021). SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3. The American Journal of Surgical Pathology, 45(8), 1108-1117. [More Information]
Mino-Kenudson, M., Le Stang, N., Daigneault, J., Nicholson, A., Cooper, W., Roden, A., Moreira, A., Thunnissen, E., Papotti, M., Pelosi, G., et al (2021). The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. Journal of Thoracic Oncology, 16(4), 686-696. [More Information]
Paver, E., O'Toole, S., Cheng, X., Mahar, A., Cooper, W. (2021). Updates in the molecular pathology of non-small cell lung cancer. Seminars in Diagnostic Pathology, 38(5), 54-61. [More Information]

show 11 more

2020

Moreira, A., Ocampo, P., Xia, Y., Zhong, H., Russell, P., Minami, Y., Cooper, W., Yoshida, A., Bubendorf, L., Papotti, M., et al (2020). A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 15(10), 1599-1610. [More Information]
Hendry, S., Byrne, N., Christie, M., Steinfort, D., Irving, L., Wagner, C., Ellwood, T., Cooper, W., Fox, S. (2020). Adequate tumour cellularity is essential for accurate PD-L1 immunohistochemistry assessment on cytology cell block specimens. Cytopathology, 31(2), 90-95. [More Information]
Itchins, M., Lau, B., Hudson, A., Westman, H., Xia, C., Hayes, S., Howell, V., Rodriguez, M., Cooper, W., Wei, G., Buckland, M., Li, B., Gill, A., Clarke, S., Pavlakis, N., et al (2020). ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. The Oncologist, 25(8), 641-649. [More Information]
Teoh, A., Jo, H., Chambers, D., Symons, K., Walters, E., Goh, N., Glaspole, I., Cooper, W., Reynolds, P., Moodley, Y., Corte, T. (2020). Blood monocyte counts as a potential prognostic marker for IPF: Analysis from the Australian IPF registry. European Respiratory Journal, 55(4), 1901855. [More Information]
Clynick, B., Jo, H., Corte, T., Glaspole, I., Grainge, C., Hopkins, P., Reynolds, P., Chapman, S., Haydn Walters, E., Zappala, C., Cooper, W., Mahar, A., et al (2020). Circulating RNA differences between patients with stable and progressive idiopathic pulmonary fibrosis. European Respiratory Journal, 56(3), 1902058. [More Information]
Troy, L., Grainge, C., Corte, T., Williamson, J., Vallely, M., Cooper, W., Mahar, A., Myers, J., Lai, S., Mulyadi, E., Torzillo, P., Jo, H., Harris, B., Lau, E., et al (2020). Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. The Lancet Respiratory Medicine, 8(2), 171-181. [More Information]
Smith, M., Hariri, L., Mino-Kenudson, M., Dacic, S., Attanoos, R., Borczuk, A., Colby, T., Cooper, W., Jones, K., Leslie, K., et al (2020). Histopathologic assessment of suspected idiopathic pulmonary fibrosis: Where we are and where we need to go. Archives of Pathology & Laboratory Medicine, 144(12), 1477-1489. [More Information]
Travis, W., Dacic, S., Wistuba, I., Sholl, L., Adusumilli, P., Bubendorf, L., Bunn, P., Cascone, T., Chaft, J., Chen, G., Cooper, W., et al (2020). IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 15(5), 709-740. [More Information]
John, T., Cooper, W., Wright, G., Siva, S., Solomon, B., Marshall, H., Fong, K. (2020). Lung Cancer in Australia. Journal of Thoracic Oncology, 15(12), 1809-1814. [More Information]
Lau, E., Grainge, C., Williamson, J., Corte, T., Cooper, W., Phillips, M., Torzillo, P., Vallely, M., Raghu, G., Troy, L. (2020). Methodologies of COLDICE and Cryo-PID studies: details make the difference. Annals of Translational Medicine, 8(12), 781. [More Information]
Ahmadzada, T., Cooper, W., Holmes, M., Mahar, A., Westman, H., Gill, A., Nordman, I., Yip, P., Pal, A., Zielinski, R., Pavlakis, N., Nagrial, A., Daneshvar, D., Karikios, D., Grau, G., Hosseini Beheshti, E., Clarke, S., Kao, S., et al (2020). Retrospective evaluation of the use of pembrolizumab in malignant mesothelioma in a real-world Australian population. JTO Clinical and Research Reports, 1(4), 1-15. [More Information]
Li, Z., Abadir, E., Lee, K., Clarke, C., Bryant, C., Cooper, W., Pietersz, G., Favaloro, J., Silveira, P., Hart, D., Ju, X., Clark, G. (2020). Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody. Clinical & Translational Immunology, 9(7), 1-12. [More Information]
Sholl, L., Hirsch, F., Hwang, D., Botling, J., Lopez-Rios, F., Bubendorf, L., Mino-Kenudson, M., Roden, A., Beasley, M., Borczuk, A., Cooper, W., et al (2020). The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 15(9), 1409-1424. [More Information]

show 10 more

2019

Pavlakis, N., Cooper, C., John, T., Kao, S., Klebe, S., Lee, C., Leong, T., Millward, M., O'Byrne, K., Russell, P., Cooper, W., et al (2019). Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. Pathology, 51(7), 673-680. [More Information]
Luk, P., Selinger, C., Cooper, W., Mahar, A., Palme, C., O'Toole, S., Clark, J., Gupta, R. (2019). Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms. Head and Neck Pathology, 13(3), 397-414. [More Information]
Troy, L., Grainge, C., Corte, T., Williamson, J., Vallely, M., Cooper, W., Mahar, A., Lai, S., Mulyadi, E., Torzillo, P., Lau, E., et al (2019). Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study. BMJ Open Respiratory Research, 6(1), 1-8. [More Information]
Burgess, A., Goon, K., Brannan, J., Attia, J., Palazzi, K., Oldmeadow, C., Corte, T., Glaspole, I., Goh, N., Keir, G., Cooper, W., et al (2019). Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing. Respirology, 24(10), 988-995. [More Information]
Vargas, A., Selinger, C., Satgunaseelan, L., Cooper, W., Gupta, R., Stalley, P., Brown, W., Soper, J., Schatz, J., Boyle, R., Tattersall, M., Bhadri, V., Scolyer, R., Karim, R., McCarthy, S., O'Toole, S., et al (2019). FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. Asia-Pacific Journal of Clinical Oncology, 15(1), 38-47. [More Information]
Jo, H., Corte, T., Glaspole, I., Grainge, C., Hopkins, P., Moodley, Y., Chapman, S., Walters, E., Zappala, C., Allan, H., Cooper, W., Goh, N., et al (2019). Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry. BMC Pulmonary Medicine, 19(1), 1-7. [More Information]
Ahmadzada, T., Lee, K., Clarke, C., Cooper, W., Linton, A., McCaughan, B., Asher, R., Clarke, S., Reid, G., Kao, S. (2019). High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. Lung Cancer, 130, 35-41. [More Information]
Jo, H., Glaspole, I., Goh, N., Hopkins, P., Moodley, Y., Reynolds, P., Chapman, S., Walters, E., Zappala, C., Allan, H., Grainge, C., Cooper, W., Corte, T., et al (2019). Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Respirology, 24(4), 361-368. [More Information]
Toon, C., Cooper, W., Selinger, C., Berney, C., Tomlinson, J. (2019). Malignant gastrointestinal neuroectodermal tumour (GNET): neural mesenchymal tumours of the gastrointestinal tract with striking histology and EWSR1 gene rearrangement. Pathology, 51(3), 324-327. [More Information]
Woodford, R., Loh, Y., Lee, J., Cooper, W., Marschner, I., Lewis, C., Millward, M., Lord, S., Gralla, R., Yang, J., Lee, C., et al (2019). Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. Future Oncology, 15(20), 2371-2383. [More Information]
Colebatch, A., Dobrovic, A., Cooper, W. (2019). TERT gene: Its function and dysregulation in cancer. Journal of Clinical Pathology, 72(4), 281-284. [More Information]

show 8 more

2018

Ahmadzada, T., Kao, S., Reid, G., Boyer, M., Mahar, A., Cooper, W. (2018). An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 7(6), E153. [More Information]
Luk, P., Selinger, C., Mahar, A., Cooper, W. (2018). Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization. Archives of Pathology & Laboratory Medicine, 142(8), 922-928. [More Information]
Cooper, W., Barnet, M., Kao, S., Scolyer, R. (2018). Biomarkers that predict response to immunotherapy-no magic bullet. Cancer Forum, 42(1), 1-10. [More Information]
Li, Z., Ju, X., Lee, K., Clarke, C., Hsu, J., Abadir, E., Bryant, C., Pears, S., Sunderland, N., Heffernan, S., Lo, T., Fromm, P., Silveira, P., Cooper, W., Brown, C., Clark, G., Hart, D., et al (2018). CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. Haematologica, 103(4), 655-665. [More Information]
Lee, C., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., Herbst, R., Gralla, R., Mok, T., Yang, J. (2018). Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncology, 4(2), 210-216. [More Information]
Hendry, S., Byrne, D., Wright, G., Young, R., Sturrock, S., Cooper, W., Fox, S. (2018). Comparison of four PD-L1 immunohistochemical assays in lung cancer. Journal of Thoracic Oncology, 13(3), 367-376. [More Information]
Jo, H., Glaspole, I., Moodley, Y., Chapman, S., Ellis, S., Goh, N., Hopkins, P., Keir, G., Mahar, A., Cooper, W., Corte, T., et al (2018). Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulmonary Medicine, 18(1), 1-8. [More Information]
Gupta, R., Cooper, W., Selinger, C., Mahar, A., Anderson, L., Buckland, M., O'Toole, S. (2018). Fluorescent In Situ Hybridization in Surgical Pathology Practice. Advances in Anatomic Pathology, 25(4), 223-237. [More Information]
Thunnissen, E., Allen, T., Adam, J., Aisner, D., Beasley, M., Borczuk, A., Cagle, P., Capelozzi, V., Cooper, W., Hariri, L., et al (2018). Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology & Laboratory Medicine, 142(3), 408-419. [More Information]
Barnet, M., Cooper, W., Boyer, M., Kao, S. (2018). Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. Journal of Clinical Medicine, 7(6), 151. [More Information]
Itchins, M., Hayes, S., Gill, A., Cooper, W., O'Connell, R., Howell, V., Clarke, S., Pavlakis, N. (2018). Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. Asia-Pacific Journal of Clinical Oncology, 14(5), e275-e282. [More Information]
Solinas, A., Mahar, A., Cooper, W., Thompson, J., Spillane, A., Scolyer, R. (2018). Pigmented Paget's disease of the nipple mistaken for melanoma in situ: a diagnostic pitfall for the unwary. Pathology, 50(3), 364-367. [More Information]
Hendry, S., Cooper, W., Fox, S. (2018). Response to Editorial: The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back? Journal of Thoracic Oncology, 13(9), e185-e186. [More Information]
Bui, K., Cooper, W., Kao, S., Boyer, M. (2018). Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. Journal of Clinical Medicine, 7(8), 1-18. [More Information]
Barnet, M., Blinman, P., Cooper, W., Boyer, M., Kao, S., Goodnow, C. (2018). Understanding Immune Tolerance of Cancer: Re-Purposing Insights from Fetal Allografts and Microbes. BioEssays, 40(8), 1-6. [More Information]

show 12 more

2017

Jo, H., Glaspole, I., Grainge, C., Goh, N., Hopkins, P., Moodley, Y., Reynolds, P., Chapman, S., Walters, E., Cooper, W., Corte, T., et al (2017). Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal, 49(2), 1-11. [More Information]
Glaspole, I., Watson, A., Allan, H., Chapman, S., Cooper, W., Corte, T., Ellis, S., Grainge, C., Goh, N., Hopkins, P., Mahar, A., et al (2017). Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. European Respiratory Journal, 50(2), pii: 1700168. [More Information]
Barnet, M., O'Toole, S., Horvath, L., Selinger, C., Yu, B., Ng, C., Boyer, M., Cooper, W., Kao, S. (2017). EGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 12(3), 585-590. [More Information]
Sebaratnam, D., Agar, N., Cooper, W., Jackett, L. (2017). Eruptive Multifocal Cutaneous Mucinous Cysts. American Journal Of Dermatopathology, 2(6), 454-456. [More Information]
Glaspole, I., Chapman, S., Cooper, W., Ellis, S., Goh, N., Hopkins, P., Macansh, S., Mahar, A., Moodley, Y., Paul, E., Corte, T., et al (2017). Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry. Respirology, 22(5), 950-956. [More Information]
Cooper, W., Russell, P., Cherian, M., Duhig, E., Godbolt, D., Jessup, P., Khoo, C., Leslie, C., Mahar, A., Moffat, D., et al (2017). Intra- and interobserver reproducibility assessment of PD-L1 biomarker in non-small cell lung cancer. Clinical Cancer Research, 23(16), 4569-4577. [More Information]
Shakya, R., Tarulli, G., Sheng, L., Lokman, N., Ricciardelli, C., Pishas, K., Selinger, C., Kohonen-Corish, M., Cooper, W., Turner, A., et al (2017). Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer. Oncogene, 36(31), 4469-4480. [More Information]
van Zandwijk, N., Pavlakis, N., Kao, S., Linton, A., Boyer, M., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M., Bailey, D., Cooper, W., Kritharides, L., Reid, G., et al (2017). Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. The Lancet Oncology, 18(10), 1386-1396. [More Information]
Selinger, C., Li, B., Pavlakis, N., Links, M., Gill, A., Lee, A., Clarke, S., Tran, T., Lum, T., Yip, P., Horvath, L., Yu, B., O'Toole, S., Cooper, W., et al (2017). Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. Histopathology, 70(3), 402-411. [More Information]
Satgunaseelan, L., Larsen, S., Carmalt, H., Cooper, W. (2017). Spindle cell variant of diffuse large B cell lymphoma occurring in the breast. Pathology, 49(7), 784-786. [More Information]
Herath, S., Cooper, W. (2017). The novel 19G endobronchial USS (EBUS) needle samples processed as tissue “core biopsies” facilitate PD-L1 and other biomarker testing in lung cancer specimens: Case report and the view point from the respiratory physician and the pathologist. Respirology Case Reports, 5(6), 1-3. [More Information]
Szczepny, A., Rogers, S., Jayasekara, W., Park, K., McCloy, R., Cochrane, C., Ganju, V., Cooper, W., Sage, J., Peacock, C., et al (2017). The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer. Oncogene, 36(39), 5544-5550. [More Information]
Thunnissen, E., Borczuk, A., Flieder, D., Witte, B., Beasley, M., Chung, J., Dacic, S., Lantuejoul, S., Russell, P., Cooper, W., et al (2017). The use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and its Differential Diagnosis. An international reproducibility study in a demanding set of cases. Journal of Thoracic Oncology, 12(2), 334-346. [More Information]
Itchins, M., Chia, P., Hayes, S., Howell, V., Gill, A., Cooper, W., John, T., Mitchell, P., Millward, M., Clarke, S., Pavlakis, N., et al (2017). Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context. Asia-Pacific Journal of Clinical Oncology, 13, 3-13. [More Information]
Kao, S., Cheng, Y., Williams, M., Kirschner, M., Madore, J., Lum, T., Sarun, K., Linton, A., McCaughan, B., Klebe, S., van Zandwijk, N., Scolyer, R., Boyer, M., Cooper, W., Reid, G. (2017). Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 12(9), 1421-1433. [More Information]

show 12 more

2016

Kao, S., Kirschner, M., Cooper, W., Tran, T., Burgers, S., Wright, C., Korse, T., van den Broek, D., Edelman, J., Vallely, M., McCaughan, B., Pavlakis, N., Clarke, S., van Zandwijk, N., Reid, G., et al (2016). A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. British Journal of Cancer, 114(5), 524-531. [More Information]
Tran, T., Selinger, C., Kohonen-Corish, M., McCaughan, B., Kennedy, C., O'Toole, S., Cooper, W. (2016). Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases. Clinical Lung Cancer, 17(1), 30-38. [More Information]
Vargas, A., Selinger, C., Satgunaseelan, L., Cooper, W., Gupta, R., Stalley, P., Brown, W., Soper, J., Schatz, J., Boyle, R., Tattersall, M., Bhadri, V., Scolyer, R., Karim, R., McCarthy, S., O'Toole, S., et al (2016). Atypical Ewing sarcoma breakpoint region 1 fluorescence in-situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases. Histopathology, 69(6), 1000-1011. [More Information]
Kakavand, H., Walker, E., Lum, T., Wilmott, J., Selinger, C., Smith, E., Saw, R., Yu, B., Cooper, W., Long, G., O'Toole, S., Scolyer, R. (2016). BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Histopathology, 69(4), 680-686. [More Information]
Jo, H., Glaspole, I., Levin, K., McCormack, S., Mahar, A., Cooper, W., Cameron, R., Ellis, S., Cottee, A., Troy, L., Torzillo, P., Corte, T., et al (2016). Clinical impact of the interstitial lung disease multidisciplinary service. Respirology, 21(8), 1438-1444. [More Information]
Anderson, S., Sasson, S., Lee, F., Cooper, W., Larsen, S., Garsia, R. (2016). Episodic fevers and vasodilatory shock mimicking urosepsis in a patient with HIV-associated multicentric Castleman's Disease: a case report. BMC Infectious Diseases, 16(1), 53. [More Information]
Lyle, M., Haydu, L., Menzies, A., Thompson, J., Saw, R., Spillane, A., Kefford, R., Mann, G., Cooper, W., Yu, B., Scolyer, R., O'Toole, S., Long, G. (2016). The molecular profile of metastatic melanoma in Australia. Pathology, 48(2), 188-193. [More Information]
Bremnes, R., Busund, L., Kilvaer, T., Andersen, S., Richardsen, E., Paulsen, E., Hald, S., Khanehkenari, M., Cooper, W., Kao, S., et al (2016). The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. Journal of Thoracic Oncology, 11(6), 789-800. [More Information]

show 5 more

2015

Kao, S., Fulham, M., Wong, K., Cooper, W., Brahmbhatt, H., MacDiarmid, J., Pattison, S., Sagong, J., Huynh, Y., Leslie, F., Pavlakis, N., Clarke, S., Boyer, M., Reid, G., van Zandwijk, N. (2015). A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. American Journal of Respiratory and Critical Care Medicine, 191(12), 1467-1469. [More Information]
Luk, P., Yu, B., Ng, C., Mercorella, B., Selinger, C., Lum, T., Kao, S., O'Toole, S., Cooper, W. (2015). BRAF mutations in non-small cell lung cancer. Translational Lung Cancer Research, 4(2), 142-148. [More Information]
Selinger, C., Cooper, W., Lum, T., McNeil, C., Morey, A., Waring, P., Amanuel, B., Millward, M., Peverall, J., Van Vliet, C., Pavlakis, N., Gill, A., et al (2015). Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing. Histopathology, 67(5), 654-663. [More Information]
Li, B., Lee, A., O'Toole, S., Cooper, W., Yu, B., Chaft, J., Arcila, M., Kris, M., Pavlakis, N. (2015). HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. Lung Cancer, 90(3), 617-619. [More Information]
Williams, M., Kirschner, M., Cheng, Y., Hanh, J., Weiss, J., Amaro-Mugridge, N., Wright, C., Linton, A., Kao, S., Edelman, J., Vallely, M., Cooper, W., van Zandwijk, N., Reid, G., et al (2015). miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget, 6(27), 23480-23495. [More Information]
Cooper, W., Tran, T., Vilain, R., Madore, J., Selinger, C., Kohonen-Corish, M., Yip, P., Yu, B., O'Toole, S., McCaughan, B., Horvath, L., Kao, S., Boyer, M., Scolyer, R., et al (2015). PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer, 89(2), 181-188. [More Information]
Cooper, W. (2015). Preface-molecular genetics of lung cancer. Translational Lung Cancer Research, 4(2), 109-109. [More Information]
Wang, S., Yu, B., Ng, C., Mercorella, B., Selinger, C., O'Toole, S., Cooper, W. (2015). The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer. Translational Lung Cancer Research, 4(2), 119-125. [More Information]

show 5 more

2014

Tran, T., Selinger, C., Yu, B., Ng, C., Kohonen-Corish, M., McCaughan, B., Kennedy, C., O'Toole, S., Cooper, W. (2014). Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer. Journal of Clinical Pathology, 67(11), 985-991. [More Information]
Moodley, Y., Goh, N., Glaspole, I., Macansh, S., Walters, E., Chapman, S., Hopkins, P., Reynolds, P., Zappala, C., Cooper, W., Mahar, A., Corte, T., et al (2014). Australian Idiopathic Pulmonary Fibrosis Registry: Vital lessons from a national prospective collaborative project. Respirology, 19(7), 1088-1091. [More Information]
Carlino, M., Haydu, L., Kakavand, H., Menzies, A., Hamilton, A., Yu, B., Ng, C., Cooper, W., Thompson, J., Kefford, R., O'Toole, S., Scolyer, R., Long, G. (2014). Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 111(2), 292-299. [More Information]
Houang, M., Sioson, L., Clarkson, A., Watson, N., Mahtab, F., Toon, C., Raut, A., O'Toole, S., Cooper, W., Pavlakis, N., Gill, A., et al (2014). EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Pathology, 46(6), 501-508. [More Information]
O'Toole, S., Yu, B., Cooper, W. (2014). Molecular Diagnosis in Cytology and Its Place in the New Classification: A Practical Guide. The Journal of OncoPathology, 2(1), 63-73. [More Information]
Cooper, W., Fox, S., O'Toole, S., Morey, A., Frances, G., Pavlakis, N., O'Brien, K., Dettrick, A., Leong, T., Rathi, V., et al (2014). National Working Group Meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology, 10(S 2), 11-17. [More Information]
Houang, M., Toon, C., Clarkson, A., Sioson, L., Watson, N., Farzin, M., Selinger, C., Chou, A., Morey, A., Cooper, W., O'Toole, S., Gill, A. (2014). Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer. Pathology, 46(5), 383-388. [More Information]
Cooper, W., Solomon, B. (2014). Response to Mahe. Modern Pathology, 27(10), 1424-1425. [More Information]

show 5 more

2013

Cooper, W., Yu, B., Yip, P., Ng, C., Lum, T., Farzin, M., Trent, R., Mercorella, B., Clarkson, A., Kohonen-Corish, M., Horvath, L., Kench, J., McCaughan, B., Gill, A., O'Toole, S. (2013). EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. Journal of Clinical Pathology, 66(9), 744-748. [More Information]
Tran, T., Selinger, C., Kohonen-Corish, M., McCaughan, B., Kennedy, C., O'Toole, S., Cooper, W. (2013). Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer, 81(3), 462-467. [More Information]
Cooper, W., Lam, D., O'Toole, S., Minna, J. (2013). Molecular biology of lung cancer. Journal of Thoracic Disease, 5(S5), S479-S490. [More Information]

2012

Poursoltana, P., Currey, N., Pangon, L., van Kralingen, C., Selinger, C., Mahar, A., Cooper, W., Kennedy, C., McCaughan, B., Trent, R., et al (2012). Loss of heterozygosity of the Mutated in Colorectal Cancer gene is not associated with promoter methylation in non-small cell lung cancer. Lung Cancer, 77(2), 272-276. [More Information]
Wang, Y., Sebaratnam, D., Wong, J., Cooper, W., Wyburn, K., Eris, J. (2012). Urethral Stricture Caused by Schistosomiasis in a Renal Transplant Recipient. Nephrology, 17(2), 197-198. [More Information]

2011

Lau, E., Cooper, W., Bye, P., Yan, K. (2011). Difficult asthma and Churg-Strauss-like syndrome: A cautionary tale. Respirology, 16(1), 180-181. [More Information]
Cooper, W., O'Toole, S., Boyer, M., Horvath, L., Mahar, A. (2011). What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 43(2), 103-115. [More Information]

2004

Cooper, W., Shingde, M., Lee, V., Allan, R., Wills, E., Harper, C. (2004). "Rhabdoid Meningioma" Lacking Malignant Features. Report Of Two Cases. Clinical Neuropathology, 23(1), 16-20.

Faculty of Medicine and Health

Page not found

Professor Wendy Cooper

Publications

By Type

By Year